Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;292(1):103-115.
doi: 10.1111/joim.13482. Epub 2022 Mar 31.

One-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individuals

Affiliations

One-year persistent symptoms and functional impairment in SARS-CoV-2 positive and negative individuals

Mayssam Nehme et al. J Intern Med. 2022 Jul.

Abstract

Background: Persistent symptoms of SARS-CoV-2 are prevalent weeks to months following the infection. To date, it is difficult to disentangle the direct from the indirect effects of SARS-CoV-2, including lockdown, social, and economic factors.

Objective: The study aims to characterize the prevalence of symptoms, functional capacity, and quality of life at 12 months in outpatient symptomatic individuals tested positive for SARS-CoV-2 compared to individuals tested negative.

Methods: From 23 April to 27 July 2021, outpatient symptomatic individuals tested for SARS-CoV-2 at the Geneva University Hospitals were followed up 12 months after their test date.

Results: At 12 months, out of the 1447 participants (mean age 45.2 years, 61.2% women), 33.4% reported residual mild to moderate symptoms following SARS-CoV-2 infection compared to 6.5% in the control group. Symptoms included fatigue (16% vs. 3.1%), dyspnea (8.9% vs. 1.1%), headache (9.8% vs. 1.7%), insomnia (8.9% vs. 2.7%), and difficulty concentrating (7.4% vs. 2.5%). When compared to the control group, 30.5% of SARS-CoV-2 positive individuals reported functional impairment at 12 months versus 6.6%. SARS-CoV-2 infection was associated with the persistence of symptoms (adjusted odds ratio [aOR] 4.1; 2.60-6.83) and functional impairment (aOR 3.54; 2.16-5.80) overall, and in subgroups of women, men, individuals younger than 40 years, those between 40-59 years, and in individuals with no past medical or psychiatric history.

Conclusion: SARS-CoV-2 infection leads to persistent symptoms over several months, including in young healthy individuals, in addition to the pandemic effects, and potentially more than other common respiratory infections. Symptoms impact functional capacity up to 12 months post infection.

Keywords: SARS; epidemiology; functional impairment; infectious diseases; inflammation; internal medicine; persistent symptoms; post-COVID.

PubMed Disclaimer

Conflict of interest statement

The authors declare no potential conflict of interest. Furthermore, we confirm that the manuscript has been read and approved by all the named authors, and that there are no other persons who satisfied the criteria for authorship but are not listed. We further confirm that this work was conducted with the ethical approval of the Cantonal Research Ethics Commission of Geneva, Switzerland, and that the approvals are acknowledged in the manuscript.

Figures

Fig. 1
Fig. 1
Flowchart.
Fig. 2
Fig. 2
Associations between laboratory‐confirmed SARS‐CoV‐2 infection and the persistence of symptoms and functional impairment at 1 year stratified by sex, age categories, and pre‐existing medical conditions (n = 1245). The persistence of symptoms was defined as the presence of any one symptom within the 2 weeks before the questionnaire. Functional impairment was assessed using the Sheehan Disability Scale [33]. Odds ratios were adjusted for time from infection, age, sex, education, profession, working in healthcare setting, smoking, physical activity, COVID‐19 vaccination status, symptoms at presentation, hospitalization, and the following comorbidities present prior to testing: overweight or obese, hypertension, respiratory disease, cardiovascular disease, diabetes, immunosuppression, hypothyroidism, anemia, migraine, tension headache, sleeping disorder, anxiety, depression, any psychiatric condition, irritable bowel syndrome, chronic pain syndrome, and chronic fatigue. aOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio.

References

    1. National Institutes of Health (NIH) . When COVID‐19 symptoms linger: new NIH initiative seeks to understand why some people continue to have symptoms long after recovery. https://covid19.nih.gov/news‐and‐stories/when‐COVID‐19‐symptoms‐linger (2021). Accessed 22 Aug 2021.
    1. National Institute for Health and Care Excellence . NICE, SIGN and RCGP set out further details about the UK guideline on management of the long‐term effects of COVID‐19. https://www.nice.org.uk/news/article/nice‐sign‐and‐rcgp‐set‐out‐further‐... (2020). Accessed 22 Aug 2021.
    1. World Health Organization . A clinical case definition of post COVID‐19 condition by a Delphi consensus. https://apps.who.int/iris/bitstream/handle/10665/345824/WHO‐2019‐nCoV‐Po... (2021). Accessed 10 Oct 2021.
    1. Nehme M, Braillard O, Alcoba G, Aebischer Perone S, Courvoisier D, Chappuis F, et al. COVID‐19 symptoms: longitudinal evolution and persistence in outpatient settings. Ann Intern Med. 2020;174:723–5. 10.7326/M20-5926 - DOI - PMC - PubMed
    1. Logue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in adults at 6 months after COVID‐19 infection. JAMA Netw Open. 2021;4(2):e210830. 10.1001/jamanetworkopen.2021.0830 - DOI - PMC - PubMed

Publication types